Scholarly Journals In Blood Biomarker

Scholarly journals are generally academic journals that encourage academic and scientific research. These journals generally prefer to publish original works, conducted following a systematic research methodology. The articles published in the scholarly journals are critically evaluated following in-depth analysis of the research data. Scholarly Journal articles strictly adhere to a standard format of writing. Once the author accomplishes their task of writing following the standard format and submits the manuscript for publication, it is the responsibility of the scholarly journal to verify whether it is written as per the academic and research norms. Scholarly journals hence subject like medical and clinical articles for a blind peer review or double peer review system and expect the authors to correct and resubmit the research articles as per the expert opinion. Alzheimer’s disease (AD) is diagnosed at a stage where neuronal loss is important, leading to severe cognitive deficits. Yet it is difficult to diagnose because of confounding clinical manifestations similar in other dementias. Clinicians thus resort to the longitudinal neurologic observation of disease progression, associated with biological markers such as Aβ 1-42, t-tau and p-tau CSF level and the measure of associated neuroanatomical insults using neuroimaging. Mild cognitive impairment (MCI) precedes AD, but is also present during normal or pathological ageing associated with other dementias. Over the course of 5 years, 50 to 70% of MCI patients will develop AD. ICDD is interested in the identification of prodromal markers of AD associated with disease progression. ICDD is a partner of the IMI/PharmaCog, consortium dedicated to the identification of new tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines. For this purpose, specific and robust biological markers are needed to follow disease progression and its potential reversal by disease-modifying drugs. Our efforts are focused on the validation of a novel set of inflammatory blood biomarkers within a cohort of 150 patients followed longitudinally for 3 years. An overview of the validation stage of existing blood biomarkers is presented, with a particular focus on inflammation markers. We will also present the two discovery platforms used to generate the marker sets being validated in the PharmaCog consortium using proprietary cellulomic and proteomic technologies. (Nathalie Compagnone, Nicolas Pelletier and ClotildeBiscarrat, Identification of blood biomarkers associated to MCI conversion into AD – The PharmaCog cohort)

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024